Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/90899
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy
Author: Keefe, D.
Elting, L.
Nguyen, H.
Grunberg, S.
Aprile, G.
Bonaventura, A.
Selva-Nayagam, S.
Barsevick, A.
Koczwara, B.
Sonis, S.
Citation: Cancer Chemotherapy and Pharmacology, 2014; 74(4):675-680
Publisher: Springer Berlin Heidelberg
Issue Date: 2014
ISSN: 0344-5704
1432-0843
Statement of
Responsibility: 
Dorothy M. Keefe, Linda S. Elting, Hoang T. Nguyen, Steven M. Grunberg, Giuseppe Aprile, Antony Bonaventura, Sudarsha Selva-Nayagam, Andrea Barsevick, Bogda Koczwara, and Stephen T. Sonis
Abstract: BACKGROUND: Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance. Epidemiology remains poorly described, and effects of multi-cycle regimens have not been investigated. To better understand the risks, symptom burden and consequences of CID, we studied patients receiving chemotherapy for colorectal cancer (CRC). METHODS: One hundred and fourteen patients receiving FOLFOX (95 patients, 530 cycles), FOLFOX + monoclonal antibodies (10 patients, 49 cycles) or FOLFIRI (9 patients, 50 cycles) were enrolled. CID was identified from diaries at baseline and daily during up to 8 chemotherapy cycles using supplemental questions on the Oral Mucositis Daily Questionnaire, a valid tool for collecting patient-reported outcomes of regimen-related mucosal injury. Patients scored CID severity from 0 "none" to 10 "worst possible," and quantity from "little" to "severe" on a 5-point scale. Quality of life was measured using the FACT-G, and fatigue using the FACIT fatigue scale. RESULTS: CID occurred in 89% of patients on FOLFIRI, 50% on FOLFOX + monoclonal antibodies and 56% on FOLFOX alone. The risk of a first episode was highest during Cycle 1 (35 %) and dropped to <10% during Cycles 3-5. Patients with CID reported poorer quality of life scores than those without CID (77.1 vs 80.7). CONCLUSIONS: Diarrhea occurs more commonly than typically appreciated during chemotherapy for CRC. Risk is highest during first exposure, suggesting variable susceptibility. Identification of this high-risk subgroup for prophylaxis could improve the quality of life.
Keywords: Chemotherapy-induced diarrhea; Chemotherapy; Colorectal cancer; Patient-reported outcomes; Quality of life
Rights: © Springer-Verlag Berlin Heidelberg 2014
RMID: 0030014697
DOI: 10.1007/s00280-014-2526-5
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.